Dyne Therapeutics (DYN) Total Liabilities (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Total Liabilities data on file, last reported at $214.9 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 312.46% year-over-year to $214.9 million in Q1 2026; TTM through Mar 2026 was $214.9 million, a 312.46% increase from a year earlier, with the FY2025 full-year figure at $214.8 million, up 249.91% from the prior year.
• Total Liabilities for Q1 2026 stood at $214.9 million, roughly flat from $214.8 million in the prior quarter.
• Over the last five years, Total Liabilities for DYN reached as high as $214.9 million in Q1 2026 and fell as low as $44.2 million in Q1 2024.
• Historically, Total Liabilities has averaged $85.9 million across 5 years, with a median of $53.2 million in 2023.
• Across the five-year window, Total Liabilities decreased 16.8% in 2024 and jumped 312.46% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $54.0 million in 2022, then surged by 36.75% to $73.8 million in 2023, then dropped by 16.8% to $61.4 million in 2024, then soared by 249.91% to $214.8 million in 2025, then gained by 0.03% to $214.9 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $214.9 million in Q1 2026, $214.8 million in Q4 2025, and $175.3 million in Q3 2025.